Cortactin can promote cell migration, cell mortality, and tumor invasiveness in melanoma, colorectal cancer, and glioblastoma [33,34], and its expression was demonstrated to be significantly associated with poorer survival rates in patients with OSCC [54,55,56]. This evidence concerns the gene CTTN and colorectal cancer.